Mark S. Shearman

7.5k citations

96 papers · 6.0k indexed · 2 hit papers · h-index 42

Impact in

Physiology top 0.5%
- Alzheimer's disease research and treatments
Pharmacology top 0.5%
- Cholinesterase and Neurodegenerative Diseases

Papers in

Physiology 54
- Alzheimer's disease research and treatments 51
Pharmacology 21
- Cholinesterase and Neurodegenerative Diseases 20

Co-authors: Dirk Beher Yasutomi Nishizuka Earl E. Clarke Alan Nadin Huw D. Lewis José L. Castro Stuart Hawtin Jonathan D.J. Wrigley
Journals: Bioorganic & Medicinal Chemistry Letters (12 papers)Journal of Biological Chemistry (9 papers)Journal of Neurochemistry (6 papers)FEBS Letters (6 papers)Biochemical Society Transactions (5 papers)
Partner nations: United States United Kingdom Japan

In The Last Decade

Mark S. Shearman

95 papers receiving 5.9k citations

Hit Papers

align trajectories log scale

Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1 2000 · 738 citations

Peers

Countries citing papers authored by Mark S. Shearman

Since Specialization

Citations

This map shows the geographic impact of Mark S. Shearman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Shearman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Shearman more than expected).

Fields of papers citing papers by Mark S. Shearman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Shearman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Shearman. The network helps show where Mark S. Shearman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark S. Shearman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark S. Shearman Line = papers co-authored together Mark S. Shearman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of Neutralizing Anti-AAV Antibodies on Vector Transduction Following Intravitreal Administration of AAV in Non-Human Primates Investigative Ophthalmology & Visual Science ·Heikki Turunen, Adrian M. Timmers, Judith A. Newmark, Steven Pennock, Mark S. Shearman	2019	1
2	Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice PubMed ·Chunjuan Song, Thomas J. Conlon, Wen‐Tao Deng, Kirsten E. Coleman, Ping Zhu, D. Berge, Shuang Wang, В В Находкин, Kari B. Green, L. Bodsworth, Alok Sharma, Adrian M. Timmers, Paulette M. Robinson, David R. Knop, William W. Hauswirth, Jeffrey D. Chulay, Mark S. Shearman, Guojie Ye	2018	16
3	Safety and Efficacy Evaluation of rAAV2tYF-PR1.7-hCNGA3 Vector Delivered by Subretinal Injection in CNGA3 Mutant Achromatopsia Sheep PubMed ·E. Gootwine, Ron Ofri, Eyal Banin, Alexey Obolensky, Edward Averbukh, José Miguel Fernández Urbina, Peiyu Hou, Hen Honig, Alexander Rosov, Wan-Tao CAI, Guojie Ye, David R. Knop, Paulette M. Robinson, Jeffrey D. Chulay, Mark S. Shearman	2017	30
4	Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy Neuropharmacology ·Danielle Graham, Audrey Gray, John A. Joyce, Dongzi Yu, Jill O’Moore, George A. Carlson, Mark S. Shearman, Tammy Dellovade, Heike Hering	2013	89
5	Triazoloamides as potent γ-secretase modulators with reduced hERG liability Bioorganic & Medicinal Chemistry Letters ·Christian Fischer, Susan L. Zultanski, Hua Zhou, Joey L. Methot, Sanjiv Shah, Hugh Nuthall, Bethany Hughes, M. Spini, Robert T. Karlychek, Alexander A. Szewczak, Christopher M. Moxham, Nathan Bays, Richard E. Middleton, Benito Muñoz, Mark S. Shearman	2012	13
6	Oral Treatment with a γ-Secretase Inhibitor Improves Long-Term Potentiation in a Mouse Model of Alzheimer's Disease Journal of Pharmacology and Experimental Therapeutics ·Matthew Townsend, Yujie Qu, Audrey Gray, Zhenhua Wu, Zhou Guang-tia, Mike Hutton, Mark S. Shearman, Richard E. Middleton	2010	35
7	Fenton chemistry and oxidative stress mediate the toxicity of the β‐amyloid peptide in a Drosophila model of Alzheimer’s disease European Journal of Neuroscience ·Thomas Rival, Richard Page, Geneveave Barbo, F Hemmer, Edward J. Ryder, Nuno Pico, Huw D. Lewis, Thomas W. Rosahl, Robert C. Hider, Luiz Miguel Camargo, Mark S. Shearman, Damian C. Crowther, David A. Lomas	2009	144
8	3-Substituted gem-cyclohexane sulfone based γ-secretase inhibitors for Alzheimer’s disease: Conformational analysis and biological activity Bioorganic & Medicinal Chemistry Letters ·Richard A. Jelley, Jason Elliott, Karl R. Gibson, Timothy Harrison, Dirk Beher, Earl E. Clarke, Huw D. Lewis, Mark S. Shearman, Jonathan D.J. Wrigley	2006	14
9	The Novel γ Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse Journal of Pharmacology and Experimental Therapeutics ·Jonathan D. Best, David W. Smith, Michael Reilly, Ruth O’Donnell, Huw D. Lewis, Amss Cas, Neil Wilkie, Thomas W. Rosahl, In-Gyu Im, Takanobu SHIGETA, Ian Churcher, John Atack, Timothy Harrison, Mark S. Shearman	2006	64
10	A comparative assessment of γ-secretase activity in transgenic and non-transgenic rodent brain Journal of Neuroscience Methods ·Julian Goggi, Huw D. Lewis, Joanie Mok, Tim J. Harrison, Mark S. Shearman, John Atack, Jonathan D. Best	2006	4
11	3,4-Fused cyclohexyl sulfones as γ-secretase inhibitors Bioorganic & Medicinal Chemistry Letters ·Duncan Shaw, Jonathan D. Best, M. Szewczuk, Alan Nadin, Mark S. Shearman, S Sochocky, Samuel Njoroge, Michael Reilly, Brian J. Williams, Jonathan D.J. Wrigley, Timothy Harrison	2006	22
12	The geminal dimethyl analogue of Flurbiprofen as a novel Aβ42 inhibitor and potential Alzheimer’s disease modifying agent Bioorganic & Medicinal Chemistry Letters ·Nicholas Stock, Benito Muñoz, Jonathan D.J. Wrigley, Mark S. Shearman, Dirk Beher, Samuel Njoroge, Toni Williamson, Gretchen Bain, Weichao Chen, Xiaohui Jiang, Hans F. M. Reijnders, Peppi Prasit	2006	19
13	Fatty acids increase presenilin-1 levels and γ-secretase activity in PSwt-1 cells Journal of Lipid Research ·Yanzhu Liu, Lin Yang, Karin Conde‐Knape, Dirk Beher, Mark S. Shearman, Neil S. Shachter	2004	28
14	Involvement of Caspases in Proteolytic Cleavage of Alzheimer’s Amyloid-β Precursor Protein and Amyloidogenic Aβ Peptide Formation Cell ·François G. Gervais, Daigen Xu, George S. Robertson, John P. Vaillancourt, Julia Sieß, Jingqi Huang, Andréa C. LeBlanc, David W. Smith, Michael Rigby, Mark S. Shearman, Earl E. Clarke, Hui Zheng, 龍子佐藤, Абдусаттар Ахатович Насиров, Nancy A. Thornberry, Amer Mohioddin Shashi Kumar P Srinu, Robert Zamboni, Sophie Roy, Donald W. Nicholson Hit paper breakdown →	1999	673
15	Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β-amyloid in rat PC12 cells Neuroscience Letters ·Scott J. Pollack, Katherine Smits, Stuart Hawtin, Chakamas Wongkhalaung and Vichien Leelawatcharamas Jantima Japakaset, Mark S. Shearman	1995	91
16	Formation of Signal Transfer Complexes between Stem Cell and Platelet-Derived Growth Factor Receptors and SH2 Domain Proteins in Vitro Biochemistry ·Ronald Herbst, Mark S. Shearman, Bahija Jallal, Joseph Schlessinger, Axel Ullrich	1995	32
17	Protein kinase C subspecies in adult rat hippocampal synaptosomes Activation by diacylglycerol and arachidonic acid FEBS Letters ·Mark S. Shearman, Tetsutaro Shinomura, Tomiichiro Oda, Yasutomi Nishizuka	1991	47
18	A rapid method for the resolution of protein kinase C subspecies from rat brain tissue Methods in enzymology on CD-ROM/Methods in enzymology ·Mark S. Shearman, Kouji Ogita, Ushio Kikkawa, Yasutomi Nishizuka	1989	20
19	Selective activation of the γ‐subspecies of protein kinase C from bovine cerebellum by arachidonic acid and its lipoxygenase metabolites FEBS Letters ·Mark S. Shearman, Zvi Naor, Kazuo Sekiguchi, Akira Kishimoto, Yasutomi Nishizuka	1989	163
20	The common structure and activities of four subspecies of rat brain protein kinase C family FEBS Letters ·Ushio Kikkawa, Kouji Ogita, Yoshitaka Ono, Yoshinori Asaoka, Mark S. Shearman, Tomoko Fujii, Katsuhiko Ase, Kazuo Sekiguchi, Koichi Igarashi, Yasutomi Nishizuka	1987	116

About Mark S. Shearman

Mark S. Shearman is a scholar working on Physiology, Pharmacology, Cellular and Molecular Neuroscience, Molecular Biology and Computational Theory and Mathematics, having authored 96 papers that have together received 6.0k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (51 papers), Cholinesterase and Neurodegenerative Diseases (20 papers), Computational Drug Discovery Methods (14 papers), Prion Diseases and Protein Misfolding (11 papers), Drug Transport and Resistance Mechanisms (11 papers), Protein Kinase Regulation and GTPase Signaling (10 papers), Neuroscience and Neuropharmacology Research (10 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (7 papers). The work is most often cited by research in Physiology (3.2k citations), Pharmacology (1.2k citations), Cellular and Molecular Neuroscience (1.2k citations), Computational Theory and Mathematics (795 citations) and Molecular Biology (3.4k citations). Mark S. Shearman has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Dirk Beher, Yasutomi Nishizuka, Earl E. Clarke, Alan Nadin, Huw D. Lewis, José L. Castro, Stuart Hawtin, Jonathan D.J. Wrigley, Adrian L. Smith and Ushio Kikkawa. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Biological Chemistry, Journal of Neurochemistry, FEBS Letters and Biochemical Society Transactions.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact